Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T12:05:30.892Z.
Calculation as of: 2026-10-06T12:05:30.892Z.
Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 66e3eaee1cdd755dffe0dd2f4d89b3fc137545160e5faabf240127d9674bae42
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$192.97M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$184.12M
EV/Sales Ratio
2.70x
TTM Avg
2.94x
3Y Avg
2.11x
5Y Avg
1.52x
Market Cap
$179.70M
EV/Sales Ratio
95.23x
TTM Avg
300.14x
3Y Avg
300.14x
5Y Avg
300.14x
Market Cap
$176.96M
EV/Sales Ratio
4.47x
TTM Avg
4.13x
3Y Avg
7.09x
5Y Avg
29.38x
Market Cap
$174.17M
EV/Sales Ratio
2.58x
TTM Avg
23.43x
3Y Avg
22.39x
5Y Avg
15.48x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | $202.05M | N/A | N/A | N/A | N/A |
| Electra Therapeutics Inc. (ETRA)vs › | $206.61M | N/A | N/A | N/A | N/A |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $192.97M | N/A | N/A | N/A | N/A |
| Compugen Ltd. (CGEN)vs › | $218.42M | 2.85x | 9.07x | 6.60x | 11.04x |
| Journey Medical Corporation (DERM)vs › | $184.12M | 2.70x | 2.94x | 2.11x | 1.52x |
| Alector, Inc. (ALEC)vs › | $220.94M | 13.98x | 7.34x | 5.26x | 6.10x |
| Canton Strategic Holdings Inc (CNTN)vs › | $179.70M | 95.23x | 300.14x | 300.14x | 300.14x |
| Cue Biopharma, Inc. (CUE)vs › | $176.96M | 4.47x | 4.13x | 7.09x | 29.38x |
| Precision BioSciences, Inc. (DTIL)vs › | $174.17M | 2.58x | 23.43x | 22.39x | 15.48x |
| Coherus Oncology, Inc. (CHRS)vs › | $173.04M | 2.51x | 2.39x | 2.07x | 2.67x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
